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Abstract 
Following neuronal disorders, astrocytes carry out either neuroprotection or neurodegeneration. Previous 
authors suggest that favoring of neurodegeneration or neuroprotection by astrocytes can be due to many 
factors such as the influence of cytokines following their binding on their receptors on astrocytes. These 
receptors have however been shown to be region specific and heterogeneous. Further, research 
exploiting their role and influence in determining astrocytic response remains partly elucidated. A review 
of previous and ongoing research on these receptors would be helpful in the disclosure of astrocytic 
responses to neuronal disorders. 
Keywords: Astrogliosis, Heterogenous astrocyte expression, Antagonistic astrocyte reaction, Nervous injury, 
Astrocyte mediated neurodegeneration 
INTRODUCTION 
Astrocytes are the most abundant macroglial 
cells in the central nervous system (Min et al, 
2006). Their fundamental roles include 
nourishment of nerves (Garey, 2003), glial scar 
formation (Huang et al, 2014), nitric acid 
synthesis (Heales et al, 2004), and ion 
hemostasis (Ridet et al, 1997). 
During neuronal disorders, astrocytes have been 
linked to neurodegeneration by causing 
leukocyte infiltration (Sonfroniew, 2000), blood 
brain barrier disruption (Cabezas et al, 2014) and 
facilitating glial scar formation (Sonfroniew, 
2009), which inhibits neuronal growth. However, 
in other instances, they have been shown to 
facilitate neuroprotection by supporting axonal 
growth (Gage et al, 1988), aiding in the 
formation and release of glutathione (Belanger, 
2009) and aiding in the reformation of disrupted 
blood brain barriers (Cabezas et al, 2014).  
It has been suggested that this antagonistic 
astrocytic response can be due to many factors 
such as the influence of either 
neurodegenerative or neuroprotective cytokines 
following their binding on their receptors on the 
astrocytes (Yunlong et al, 2011). For example, if 
macroglial cells secrete a neurodegenerative 
cytokine such as Tumor Necrosis Factor 
following nervous disorders, this cytokine can 
influence astrocyte mediated neurodegeneration 
from the astrocyte upon which it binds. On the 
other hand, if a neuroprotective cytokine such as 
interleukin 6 is secreted, it can influence 
neuroprotective effects. 
Unfortunately, it has been hinted that the 
receptors for the different cytokines/ligands that 
may influence astrocyte reaction, exhibit region 
specific heterogeneity (Zhang and Barres, 2010; 
Oberheim et al, 2012). This means that 
astrocytes located in one part of the brain may 
not necessarily share the same receptors as 
those located in a different part of the brain. 
Hence, if the receptors of a particular 
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cytokine/ligand are missing on the astrocytes 
around where it is secreted, its effects may not 
be observed.  
Even though studies have hinted on the region 
specific heterogeneous nature of the receptors 
found on astrocytes, their influence in 
determining astrocyte response to neuronal 
disorders remains to be elucidated (Zhang and 
Barres, 2010).  
Astrocytic reaction to nerve injury has been 
linked to astrocyte mediated neurodegenerative 
diseases like Alzheimer’s Disease and Parkinson’s 
disease whose prevalence is not only high but 
has been increasing (Denis et al, 1989; Lau and 
Breteler, 2006). Therefore, the role played by 
the region specific and heterogeneous nature of 
astrocyte receptors may be important in 




Literature was searched using Google, Hinari 
Scholar and PubMed for controlled and 
experimental studies. Search items in the 
databases were ‘roles of astrocytes in 
neurodegenerative diseases’, ‘astrogliosis’ , ‘glial 
scar formation’ , 'astrocyte receptors', 
'cytokines’, ‘astrocytes' and ‘reactive astrocytes’. 
Any additional relevant studies from the 
reference lists of these papers were also 
included. Both human studies and animal model 
studies were included. Out of 45 potential 
papers, only 28 papers were used. The 17 
papers that were not used were only provided 




Role of the astrocyte receptors in 
determining astrocytic response 
Heterogeneity in astrocyte receptors   
Studies on astrocytic receptors have hinted that 
that their expression varies from region to region 
(Zhang and Barres, 2010). Among the receptors 
that have been reported to vary are those of 
glutamate, erB and Il-6 (Marz et al, 1999; Zhang 
and Barres, 2010; Oberheim et al, 2012). For this 
review, these receptors were selected amongst 
others due to their variant expression as 
compared to the rest. 
Heterogeneity of Glutamate astrocyte 
receptors 
Astrocytes have been shown to express 
glutamate receptors that enable them to sense 
and respond to neuronal activity. Among the 
glutamate receptors that have been shown to 
vary depending on the brain region is the α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid (AMPA) receptors. These receptors are 
found mostly in astrocytes of the cerebellum, 
neocortex and brain stem unlike other parts of 
the brain (Hoft et al, 2014). AMPA receptors in 
cortical astrocytes are important in neuron-glia 
signaling as well as regulation of levels of 
glutamate at the synaptic cleft (Hoft et al, 2014). 
This regulation occurs through the absorption of 
excess glutamate following synaptic release of 
the neurotransmitter during nerve firing. This 
absorption prevents glutamate excito-toxicity, 
which is the accumulation of glutamate in the 
synaptic cleft (Anderson and Swanson, 2000). 
Excito-toxicity has been shown to occur in areas 
where the glutamate receptors are deficient or 
non-functional. Therefore, in areas such as the 
hippocampus, where glutamate receptors are 
deficient,  excito-toxicity and hence 
neurodegeneration are prone following excess 
glutamate accumulation in the synaptic cleft as 
compared to other areas such as cerebellum, 
neocortex and brain stem where these 
glutamate receptors are abundant on the 
astrocytes. This is further supported by the fact 





that Alzheimer’s disease (Sheldon and Robinson, 
2007), which usually occurs following 
dysfunctional neurons in the hippocampus has 
been linked to glutamate toxicity. In excito-
toxicity, the excess glutamate binds to N-Methyl-
D-aspartate receptor on the post synaptic 
membrane of nerves following failure of its total 
absorption into the astrocyte (Lau and 
Tymianski, 2010). This has been suggested to 
lead to increased Ca2+ influx in the surrounding 
nerve and activation of a number of enzymes, 
including phospholipases, endonucleases, and 
proteases such as calpain. These enzymes go on 
to damage nerve cell structures such as 
components of the cytoskeleton, membrane, 
and DNA (Lau and Tymianski, 2010). This may 
explain the nervous dysfunction in Alzheimer’s 
disease. 
Heterogeneity of erB astrocyte receptors 
The erB family of proteins are receptor tyrosine 
kinases whose role in the central nervous system 
is neuron to glia communication (Sharif et al, 
2009). In humans, the family of erB includes erB 
1, erB 2, erB 3 and erB 4 receptors. These 
receptors are also identified as the HER 
receptors in humans (Casalini et al, 2004). They 
bind several ligands referred to as Epidermal 
Growth Factor related peptide growth factors. 
These stimulate the intrinsic tyrosine kinase 
activity of the receptors and triggers auto 
phosphorylation of specific tyrosine residues in 
the astrocyte cytoplasm (Sharif et al, 2009). 
These residues finally provide sites for 
downstream signaling molecules and eventually 
facilitate the effects of the growth factor. Just 
like the glutamate receptors, the erB receptors 
have been shown to vary within different brain 
regions with cortical astrocytes expressing 
erbB1, erbB2, and erbB3, whereas human 
hypothalamic astrocytes expressing erbB1, 
erbB2, and erbB4 receptors (Sharif et al, 2009). 
Recent data implicates insufficient ErbB signaling 
in neurodegenerative diseases (Gondi et al, 
2009). Insufficient erB 3 and erB 4 receptors 
have been linked to schizophrenia whereas 
alterations in erB 4 has been linked to 
Alzheimer’s disease. erB 1 and erB 2 have also 
been linked to pathophysiology of Parkinson’s 
disease. Therefore, in areas expressing erB 1 
and erB 2 receptors, nervous dysfunction might 
be common; so are the areas deficient in erB 4 
receptors (Sharif et al, 2009). 
Heterogeneity of IL-6 astrocyte receptors 
Interleukin 6(IL-6) is a cytokine not only involved 
in infection and metabolic processes but also 
neural processes. Its role in the CNS has been 
reported to be antagonistic, promoting 
inflammation in some instances and anti-
inflammation in others (Scheller et al, 2011; 
Burton and Johnson, 2012). This antagonistic 
pattern has been linked to its receptors, which 
vary regionally. The receptors of IL 6 can be 
grouped into the membrane bound IL 6 
receptors and the soluble IL 6 receptors. The 
soluble receptors are produced following 
cleaving of the membrane receptors immediately 
before the membrane-spanning region by 
alternative splicing or by proteolytic enzymes 
(Scheller et al, 2011). Research has shown that 
IL6 binding through its membrane receptors 
induces anti-inflammatory reaction. On the other 
hand, binding through the soluble IL 6 receptors 
induces pro-inflammatory reactions (Burton and 
Johnson, 2012). Unlike the soluble IL 6 receptors 
which are expressed in almost all cells, the 
membrane bound receptors have been shown to 
be highly expressed in a few cells including the 
astrocytes located in the cortex as compared to 
other areas (Marz et al, 1999). The binding of IL 
6 on these areas induces the production 
neurotrophic factors. In the cortex, for example, 
IL 6 has been shown to induce production of 
neurotrophic factor 4 and 5 (Marz et al, 1999).  
These neurotrophic factors have been shown to 
be neuroprotective. Areas with the soluble IL 6 
receptors may however be prone to astrocyte 
mediated neuro-degeneration. This differential 
receptor expression, as illustrated above, may 
explain the antagonistic astrocyte response to 
nerve injury.  
These differential receptor expression in 
astrocytes as illustrated have been linked to the 





different embryological origins of the astrocytes 
(Oberheim et al, 2012). 
Astrocyte embryology  
Embryologically, astrocytes have been reported 
to differentiate from different regions (Oberheim 
et al, 2012). Astrocytes located in the brain have 
been shown to originate in the ventricular zone 
from radial glial intermediate cells (Voigt, 1989; 
Oberheim et al, 2012). These astrocytes have 
been reported to populate the regions of the 
cortex, dorsal pallium and ventral telencephalon 
in the developing brain (Oberheim et al, 2012). 
The other source of astrocytes located in the 
brain is the Sub ventricular zone. These 
astrocytes have been reported to populate most 
of the marginal zone during embryonic brain 
development, the ganglionic emminences, dorsal 
pallium and ventral striatum (Paterson et al, 
1973; Oberheim et al, 2012). The astroblasts 
from the medial ganglionic emminence populate 
the basal ganglia and hippocampus whereas 
those of the lateral ganglionic emminence 
populate the septum and amygdala. Astrocytes 
from the caudal ganglionic emminence occupy 
the nucleus accumbens, stria terminalis and part 
of the hippocampus (Paterson et al, 1973; 
Oberheim et al, 2012). Differentiations of these 
astrocytes have been reported to be under 
regulation of many region specific molecular 
factors such as Gli and Nkx genes. Research has 
suggested that these sub types of astrocytes 
acquire heterogeneity in function due to this 
differential molecular expression during their 
embryology (Oberheim et al, 2012). 
In the spinal cord, just like in the brain, research 
has also shown a difference in the origins of 
astrocytes. In the spinal cord, astrocytes have 
been reported to originate from three domains 
that are arranged in a dorso-ventral axis 
(Chaboub and Deneen, 2012). These three 
domains are termed p1, p2 and p3 and they have 
been shown to express transcription factors Pax6 
and Nkx6.1, as well as Reelin and Slit (Figure 1) 
(Chaboub and Deneen, 2012). 
 
Similar to the brain, astrocytes within the spinal 
cord may also bear different receptor types. It is 
also possible that the different expression of 
molecular factors during their embryology in the 
spinal cord influences astrocyte receptor 
specificity, just like in the brain.  
Conclusion 
Astrocyte response following neuronal disorders 
is highly governed by distinct astrocyte receptor 




1. Anderson CM, Swanson RA. 2000. Astrocyte glutamate transport: Review of properties, 
regulation, and physiological functions. Glia; 32:1-14. 
2. Burton MD, Rodney WJ. 2012. Interleukin-6 trans-signaling in the senescent mouse brain is 
involved in infection-related deficits in contextual fear conditioning. Brain, Behavior, and 
Immunity 26; 732–738. 
3. Cabezas R, Ávila M, Janneth G, Ramon SB, Eliana B. 2014. Astrocytic modulation of blood brain 
barrier: perspectives on Parkinson’s disease. Front Cell Neuroscience; 8: 211. 





4. Casalini P, Marilena VI, Enrico G. 2004. Role of HER receptors family in development and 
differentiation. Journal of cellular Physiology; 200: 343–350. 
5. Chaboub LS, Deneen B. 2012. Developmental origins of astrocyte heterogeneity: the final frontier 
of CNS development. Developmental Neuroscience; 34: 379- 388. 
6. Denis AE, Funkenstein H, Marilyn SA. 1989. Prevalence of Alzheimer's Disease in a community 
population of older persons (higher than previously reported). JAMA; 262:2551-2556. 
7. Gage FH, Olejniczak P, Armstrong DM. 1988. Astrocytes are important for sprouting in the 
septohippocampal circuit. Exp Neurol; 102: 2-13.  
8. Garey L. 2003. Role of neuroglia in central nervous system diseases.  Bulletin et memoires de 
l'Academie royale de medicin belgium; 158:329-33. 
9. Gondi CS, Dzung HD , Jeffrey DK, Meena G. 2009. MMP-2 downregulation mediates differential 
regulation of cell death via erbb-2 in glioma xenografts. Int Journal of Oncology; 35: 257–263. 
10. Heales JR, Lam AJ, Duncan AJ, Land JM.  2004. Neurodegeneration or Neuroprotection: The 
pivotal role of astrocytes; Neurochemical Research; 29:513–519. 
11.  Höft S, Stephanie G, Gerald S, Christian S. 2014. Heterogeneity in expression of functional 
ionotropic glutamate and GABA receptors in astrocytes across brain regions: insights from the 
thalamus. Philos Trans R Soc Lond B Biology Science; 369: 20130602. 
12. Huang L, Zhe BW, Qichuan Z, WeiMing Z, Bei S, Brian W, Fen S, Kunlin J. 2014. Glial scar 
formation occurs in the human brain after ischemic stroke. International Journal of glial scar 
formation occurs in the human brain after ischemic stroke medical sciences; 11- 4: 344-348. 
13. Lau ML, Breteler MB. 2006. Epidemiology of Parkinson’s disease. Lancet Neurology; 5: 525–35. 
14. Lau ML, Tymianski M. (2010). Glutamate receptors, neurotoxicity and neurodegeneration. 
European Journal of Physiology; 460:525–542. 
15. März P, Heese K, Dimitriades-Schmutz B, Rose-John S, Otten U. 1999. Role of interleukin-6 and 
soluble IL-6 receptor in region-specific induction of astrocytic differentiation and neurotrophin 
expression. Glia; 26:191-200. 
16. Min KJ, Yang MS, Seung UK, Ilo J, Eun HJ. 2006.  Astrocytes induce hemeoxygenase-1 
expression in microglia: a feasible mechanism for preventing excessive brain inflammation. 
Journal of Neuroscience; 1-26: 1880-1887. 
17.  Bélanger M. 2009. The role of astroglia in neuroprotection. Dialogues Clinical Neuroscience; 11: 
281–295. 
18. Oberheim NC, Steven AG, and Maiken N. 2012. Heterogeneity of astrocytic form and function. 
Methods Mol Biol.; 814: 23–45. 
19. Paterson JA, Privat A, Ling EA, Leblond CP. 1973. Investigation of glial cells in semithin sections. 
III. Transformation of subependymal cells into glial cells as shown by radio autography after (3H) 
thymidine injection into the lateral ventricle of the brain of the young rat. Journal of comparative 
neurology; 149: 83-102. 
20. Ridet JL, Malhotra SK, Privat A, Gage FH. 1997. Reactive astrocytes: cellular and molecular cues 
to biological function. Trends in Neurosciences; 20:570-577. 
21. Sheldon AL,  Robinson MB.  2007. The Role of glutamate transporters in neurodegenerative 
diseases and potential opportunities for intervention. Neurochemistry Int; 51: 333–355.  
22. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. 2011. The pro- and anti-inflammatory 
properties of the cytokine Interleukin 6. Biochim Biophys Acta; 1813:878-88. 
23. Sharif A, Duhem-Tonnelle V, Allet C. 2009, Differential erbB signaling in astrocytes from the 
cerebral cortex and the hypothalamus of the human brain. Glia; 57:362-79.  





24. Sofroniew VM. 2000. Astrocyte failure as a cause of CNS dysfunction. Molecular Psychiatry; 5: 
230-232. 
25. Sonfroniew VM. 2009. Molecular dissection of reactive astrogliosis and glial scar formation. Trends 
in neurosciences; 32: 638-647. 
26. Voigt T. 1989. Development of glial cells in the cerebral wall of ferrets: Direct tracing of their 
transformation from radial glia into astrocytes. Journal of comparative neurology; 289: 74-88. 
27. Yunlong MC, Tian HC, Yong Z, Jialin Z.  2011. FOXO3a inhibits TNF-α- and IL-1β-induced astrocyte 
proliferation: implication for reactive astrogliosis. Glia. 59: 641–654. 
28. Zhang Y and Barres BA. 2010. Astrocyte heterogeneity: an underappreciated topic in neurobiology 
Current Opinion in Neurobiology 20:588–594. 
